SCHEMBL13624843

SCHEMBL13624843

CCCCOCOc1cc(B(O)O)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 4/20 0.40
PDE4B Q07343 4/20 0.39
ENPP2 Q13822 2/20 0.39
PDE4A P27815 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
PLA2G4B P0C869 1/20 0.37
FAAH O00519 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954452 0.90 SMPD1 (0.48) SMPD1PDE4BENPP2PDE4APDE4C
SCHEMBL8082305 0.84 FAAH (0.46) SMPD1ENPP2CA1CA2PLA2G4B
SCHEMBL29950801 0.82 HSD17B10 (0.44) SMPD1PDE4BENPP2PDE4APDE4D
SCHEMBL7420999 0.82 HSD17B10 (0.44) SMPD1PDE4BENPP2PDE4APDE4D
SCHEMBL1155862 0.82 CA1 (0.46) ENPP2CA1CA2SMN1; SMN2
SCHEMBL29955098 0.81 ENPP2 (0.44) PDE4BENPP2PDE4APDE4CPDE4D
SCHEMBL1963060 0.79 PDE4A (0.50) PDE4BENPP2PDE4APDE4CPDE4D
SCHEMBL1458309 0.77 LPL (0.47) SMPD1CA1CA2
SCHEMBL1721550 0.77 ENPP2 (0.38) ENPP2CA1CA2
SCHEMBL6736805 0.76 LPL (0.49) SMPD1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291924-A1 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof BIPAR SCIENCES, INC. (US) 2009-11-26 US disclosed
US-20090291924-A1 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof BIPAR SCIENCES, INC. (US) 2009-11-26 US disclosed
US-7538252-B2 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof BIPAR SCIENCES, INC. (US) 2009-05-26 US disclosed
US-7538252-B2 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof BIPAR SCIENCES, INC. (US) 2009-05-26 US disclosed
US-20080076737-A1 DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF BIPAR SCIENCES, INC. (US) 2008-03-27 US disclosed
US-20080076737-A1 DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF BIPAR SCIENCES, INC. (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291924-A1 Drug design for tubulin inhibitors, compositions, and methods of treatment thereof TUBB, TUBA1C, TUBB1 SMPD1 3507/4885PDE4B 3452/4885ENPP2 4244/4885
US-20080076737-A1 DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF TUBB, TUBA1C, TUBB1 SMPD1 3507/4885PDE4B 3452/4885ENPP2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.